Treatment of anemia with darbepoetin alfa in heart failure.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Congestive Heart Failure

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1751-7133.2010.00142.xPMID 20557327
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial

  2009cited by this paper
• The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis?

  2009cited by this paper
• Erythropoietin treatment in patients with chronic heart failure: a meta-analysis

  2009cited by this paper
• Anemia: the point of convergence or divergence for kidney disease and heart failure?

  2009cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡

  2008cited by this paper
• Anemia and mortality in heart failure patients a systematic review and meta-analysis.

  2008cited by this paper
• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

  2008cited by this paper
• Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.

  2008cited by this paper
• Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia

  2008cited by this paper
• Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.

  2007cited by this paper
• Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

  2007cited by this paper
• Anaemia and renal dysfunction are independently associated with BNP and NT‐proBNP levels in patients with heart failure

  2007cited by this paper
• Efficacy and safety of epoetin alfa in critically ill patients.

  2007cited by this paper
• Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.

  2007cited by this paper
• KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.

  2007cited by this paper
• Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial

  2007cited by this paper
• KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.

  2007cited by this paper
• Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

  2006cited by this paper
• Correction of anemia with epoetin alfa in chronic kidney disease.

  2006cited by this paper
• Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study

  2006cited by this paper
• Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

  2006cited by this paper
• Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.

  2006cited by this paper
• Prevalence of anemia and effects on mortality in patients with heart failure.

  2005cited by this paper
• Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure: Results From Val-HeFT

  2005cited by this paper
• Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients.

  2004cited by this paper
• Erythropoietin in cardiovascular diseases.

  2004cited by this paper
• Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

  2004cited by this paper
• Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States.

  2004cited by this paper
• The prognostic importance of anemia in patients with heart failure.

  2003cited by this paper
• The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.

  2003cited by this paper
• Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure

  2003cited by this paper
• Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure

  2003cited by this paper
• Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction.

  2001cited by this paper
• Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%.

  2001cited by this paper
• The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.

  2001cited by this paper
• The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

  1998cited by this paper

• The treatment of chronic anemia in heart failure: a global approach

  2023cites this paper
• Erythropoietin Therapy in Critically Ill and Acute Kidney Injury Patients

  2019cites this paper
• DEPTH Anemia and Iron Deficiency in Heart Failure Current Concepts and Emerging Therapies

  2018cites this paper
• Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies

  2018cites this paper
• Erythropoietin and the vascular wall: the controversy continues.

  2013cites this paper
• Effects of Erythropoietin on Blood Vessels and the Heart

  2013cites this paper
• Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry.

  2012cites this paper
• Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

  2011cites this paper
• Kardiorenales Anämiesyndrom – Was ist das?

  2011cites this paper
• Endogenous and exogenous erythropoietin in left ventricular dysfunction

  2010cites this paper